Stay updated on TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial

Sign up to get notified when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:38:05.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the clinical trial for patients with progressive unresectable stage III or stage IV melanoma. The change likely reflects an adjustment or development in the treatment protocol involving IFN-alpha, nivolumab, and TIL for the participants.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:30.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria'. This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    32%
    Check dated 2024-05-22T21:23:48.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:21:36.000Z thumbnail image

Stay in the know with updates to TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.